Vrajesh Bhaskarbhai Pandya

Vrajesh Bhaskarbhai Pandya

Auto-generated profile, based on publicly available information

Vrajesh Bhaskarbhai Pandya

Zydus Research Centre, Zydus Lifesciences Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad, 382213, India

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AJAmit Arvind Joharapurkar
Amit Arvind Joharapurkar
VPVrajesh Bhaskarbhai Pandya
Vrajesh Bhaskarbhai Pandya
VPVishal J. Patel
Vishal J. Patel
RDRanjit C. Desai
Ranjit C. Desai
MJMukul R Jain
Mukul R Jain

16 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VPVrajesh Bhaskarbhai Pandya
Vrajesh Bhaskarbhai Pandya
SKSanjay Kumar
Sanjay Kumar
SSSachchidanand Sachchidanand
Sachchidanand Sachchidanand
RSRajiv Sharma
Rajiv Sharma
RDRanjit C. Desai
Ranjit C. Desai

1 December 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VPVrajesh Pandya
Vrajesh Pandya
MJMukul Jain
Mukul Jain
GCGanes Chakrabarti
Ganes Chakrabarti
HSHitesh Soni
Hitesh Soni
BPBhavesh Parmar
Bhavesh Parmar
PPPankaj Patel
Pankaj Patel

15 February 2012 in Synthetic Communications
Verified
Journal Article
Closed access
VPVrajesh B. Pandya
Vrajesh B. Pandya
MJMukul R Jain
Mukul R Jain
BCBalaji V. Chaugule
Balaji V. Chaugule
JPJigar S. Patel
Jigar S. Patel
BPBhavesh M. Parmar
Bhavesh M. Parmar
PPPankaj R. Patel
Pankaj R. Patel
A convenient and high-yielding synthesis of unsymmetrical dibenzothiophenes has been achieved by an acid-mediated ring closure of the biphenyl ring having a sulfoxide substituent at the ortho position. Various functional groups are well tolerated in this methodology.

1 October 2011 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
VPVrajesh Pandya
Vrajesh Pandya
MJMukul Jain
Mukul Jain
GCGanes Chakrabarti
Ganes Chakrabarti
HSHitesh Soni
Hitesh Soni
BPBhavesh Parmar
Bhavesh Parmar
PPPankaj Patel
Pankaj Patel

2 January 2017 in Xenobiotica
Verified
Journal Article
Closed access
HPHarilal Patel
Harilal Patel
AJAmit Arvind Joharapurkar
Amit Arvind Joharapurkar
VPVrajesh Bhaskarbhai Pandya
Vrajesh Bhaskarbhai Pandya
VPVishal Jagjivanbhai Patel
Vishal Jagjivanbhai Patel
SKSamadhan Govind Kshirsagar
Samadhan Govind Kshirsagar
RDRanjit C. Desai
Ranjit C. Desai
1. ZYAN1 is a prolyl hydroxylase inhibitor in clinical development for treatment of anemia associated with chronic kidney disease (CKD). We evaluated the effect of acute and chronic kidney impairment on the pharmacokinetics of ZYAN1 in rat models. 2. Cisplatin (2.5, 5 and 7.5 mg/kg) was used to induce acute kidney injury (AKI), and five-sixth and total nephrectomy was used to induce chronic kidney injury (CKI) in male Wistar rats. All groups received a single 15 mg/kg oral dose of ZYAN1. Blood/urine samples were analyzed for ZYAN1 to assess peak concentration (Cmax), area under the concentration–time curve (AUCinf), total body clearance (CL/F) and elimination half-life (T1/2). 3. Cmax and AUCinf were not significantly different in the various AKI groups or in five-sixth nephrectomized rats, as compared to control rats. Recovery of ZYAN1 in urine was reduced; the impact on the CL/F was minimal. There was a 2-fold increase in AUCinf with reduction in CL/F in total nephrectomized rats. T1/2 was longer for ZYAN1 in the severe AKI/five-sixth nephrectomy rats and total nephrectomy rats as compared to control rats. 4. Based on the rodent data it may be inferred that PK of ZYAN1 in CKD patients may be minimally affected.